Upstream Bio has dosed the first subject in the randomised Phase II trial of verekitug, an antibody antagonist targeting the thymic stromal lymphopoietin (TSLP) receptor, in individuals with chronic obstructive pulmonary disease (COPD).
Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest biotechs to list on the Nasdaq.
RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its own ambitions at $182 million.
Upstream Bio, a clinical-stage biotech developing a monoclonal antibody to target respiratory disorders, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the completion of a $200 million Series B financing.
Until recently, venture-backed biotech companies had largely managed to shrug off the malaise that has been hurting the industry for some time. Now the inevitable has happened, with both the number of venture rounds and the amount raised taking a dive in the second quarter.
True, the numbers do not look so bad when compared against pre-2020 figures, the latest analysis of data compiled by Evaluate Pharma show. But, with the current downturn showing no sign of bottoming out, the question is how bad it might become for young private groups.
Clinical-stage program UPB-101 targets the TSLP receptor, a cytokine receptor positioned upstream in the inflammatory cascade with the potential to impact multiple diseases, including asthma